{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:21:27Z","timestamp":1788373287083,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008582","name":"McGill University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.berh.2026.102126","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:08:28Z","timestamp":1772852908000},"page":"102126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Scleromyositis \u2013 The new frontier"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6718-2468","authenticated-orcid":false,"given":"Marie","family":"Hudson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Troyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3361-6165","authenticated-orcid":false,"given":"Oc\u00e9ane","family":"Landon-Cardinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-857X(03)00023-1","article-title":"Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being","volume":"29","author":"Medsger","year":"2003","journal-title":"Rheum Dis Clin N Am"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/art.41246","article-title":"Current and future outlook on disease modification and defining low disease activity in systemic sclerosis","volume":"72","author":"Nagaraja","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2026.102126_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/art.1780210111","article-title":"Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations","volume":"21","author":"Clements","year":"1978","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0738-081X(92)90091-C","article-title":"Scleroderma\/polymyositis overlap syndromes and their immunologic markers","volume":"10","author":"Jablonska","year":"1992","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.berh.2026.102126_bib7","article-title":"Milk of calcium in scleromyositis","author":"Giraudo","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102126_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1196\/annals.1422.029","article-title":"Systemic sclerosis-associated myopathy","volume":"1108","author":"Ranque","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.berh.2026.102126_bib9","article-title":"Systemic sclerosis associated myopathy in a large single-center cohort: autoantibody profiles, histological features, and independent risk of mortality","author":"Paik","year":"2025","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2026.102126_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152672","article-title":"Imaging findings of scleroderma-associated myopathy: a systematic literature review","volume":"72","author":"Ingrid","year":"2025","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.berh.2026.102126_bib11","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"23","key":"10.1016\/j.berh.2026.102126_bib12","doi-asserted-by":"crossref","first-page":"e2068","DOI":"10.1212\/WNL.0000000000005638","article-title":"Muscular and extramuscular clinical features of patients with anti-PM\/Scl autoantibodies","volume":"90","author":"De Lorenzo","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib13","first-page":"129","article-title":"Anti-pm\/scl antibodies in connective tissue disease: clinical and biological assessment of 14 patients","volume":"24","author":"Vandergheynst","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib14","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/rheumatology\/keab492","article-title":"Autoantibody profiles delineate distinct subsets of scleromyositis","volume":"61","author":"Leclair","year":"2022","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2026.102126_bib15","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/european league against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2026.102126_bib16","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"supp 10","key":"10.1016\/j.berh.2026.102126_bib17","article-title":"ACR\/EULAR criteria for myositis and systemic sclerosis lack sensitivity for scleromyositis [abstract]","volume":"71","author":"Meyer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102126_bib18","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2013.868512","article-title":"Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian scleroderma research group (CSRG) cohort","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001357","article-title":"Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies","volume":"6","author":"Landon-Cardinal","year":"2020","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003081","article-title":"In inflammatory myopathies, dropped head\/bent spine syndrome is associated with scleromyositis: an international case-control study","volume":"9","author":"Pijnenburg","year":"2023","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib22","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000694","article-title":"Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis","volume":"7","author":"Suarez-Calvet","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/03009741003774626","article-title":"Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features","volume":"39","author":"Ranque","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102126_bib24","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3899\/jrheum.090694","article-title":"Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database","volume":"36","author":"Baron","year":"2009","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib25","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/rheumatology\/key031","article-title":"Using serum troponins to screen for cardiac involvement and assess disease activity in the idiopathic inflammatory myopathies","volume":"57","author":"Lilleker","year":"2018","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2026.102126_bib26","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.3899\/jrheum.090562","article-title":"Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/ard.2009.115568","article-title":"Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf672","article-title":"Prevalence, distribution and associations of the scleroderma capillaroscopic patterns: new insights from the Italian SPRING-SIR registry","volume":"65","author":"De Angelis","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2026.102126_bib30","article-title":"Nailfold videocapillaroscopy abnormalities in autoimmune inflammatory myopathy subsets","author":"Leclair","year":"2025","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jmri.24046","article-title":"Correlation of muscle BOLD MRI with transcutaneous oxygen pressure for assessing microcirculation in patients with systemic sclerosis","volume":"38","author":"Partovi","year":"2013","journal-title":"J Magn Reson Imag"},{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating anti-nuclear antibodies in systemic sclerosis: utility in diagnosis and disease subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J Nippon Med Sch"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib34","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3899\/jrheum.131450","article-title":"Autoantibodies to the Rpp25 component of the Th\/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests","volume":"41","author":"Mahler","year":"2014","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102126_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103608","article-title":"Reflecting on a decade of the international consensus on ANA patterns (ICAP): accomplishments and challenges from the perspective of the 7th ICAP workshop","volume":"23","author":"Andrade","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/rheumatology\/kex458","article-title":"Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1\/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis","volume":"57","author":"Pauling","year":"2018","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.berh.2026.102126_bib37","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1016\/S2665-9913(21)00244-7","article-title":"Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European scleroderma trial and research group multicentre, longitudinal registry study for very early diagnosis of systemic sclerosis (VEDOSS)","volume":"3","author":"Bellando-Randone","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102851","article-title":"Histopathological features of systemic sclerosis-associated myopathy: a scoping review","volume":"20","author":"Lefebvre","year":"2021","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/ar4562","article-title":"Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology","volume":"16","author":"Bhansing","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib40","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/BOR.0000000000000966","article-title":"Myopathy in systemic sclerosis","volume":"35","author":"Connolly","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2026.102126_bib41","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/acr.23291","article-title":"Association of fibrosing myopathy in systemic sclerosis and higher mortality","volume":"69","author":"Paik","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X16671928","article-title":"Histopathological findings in systemic sclerosis-related myopathy: fibrosis and microangiopathy with lack of cellular inflammation","volume":"9","author":"Corallo","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"SI","key":"10.1016\/j.berh.2026.102126_bib43","doi-asserted-by":"crossref","first-page":"SI82","DOI":"10.1093\/rheumatology\/keac361","article-title":"Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort","volume":"62","author":"Matas-Garcia","year":"2023","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.berh.2026.102126_bib44","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/ard.2008.095919","article-title":"A descriptive and prognostic study of systemic sclerosis-associated myopathies","volume":"68","author":"Ranque","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00401-021-02305-3","article-title":"Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology","volume":"141","author":"Siegert","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12840","article-title":"Capillary pathology with prominent basement membrane reduplication is the hallmark histopathological feature of scleromyositis","volume":"48","author":"Ellezam","year":"2022","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00401-021-02335-x","article-title":"Capillary basement membrane reduplication in myositis patients with mild clinical features of systemic sclerosis supports the concept of 'scleromyositis'","volume":"142","author":"Ellezam","year":"2021","journal-title":"Acta Neuropathol"},{"issue":"12","key":"10.1016\/j.berh.2026.102126_bib48","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102126_bib49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib51","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib52","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000434","article-title":"Immune myopathies with perimysial pathology: clinical and laboratory features","volume":"5","author":"Bucelli","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 9","key":"10.1016\/j.berh.2026.102126_bib53","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.berh.2026.102126_bib54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"issue":"13","key":"10.1016\/j.berh.2026.102126_bib55","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib56","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0000000000000552","article-title":"Muscle disease in scleroderma","volume":"30","author":"Paik","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2026.102126_bib57","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.21822","article-title":"Brachio-cervical inflammatory myopathies: clinical, immune, and myopathologic features","volume":"54","author":"Pestronk","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib58","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000410","article-title":"Brachio-cervical inflammatory myopathy with associated scleroderma phenotype and lupus serology","volume":"5","author":"Gao","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.berh.2026.102126_bib59","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nmd.2022.12.001","article-title":"Myositis with prominent B cell aggregates may meet classification criteria for sporadic inclusion body myositis","volume":"33","author":"Meyer","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/01913120802209379","article-title":"Tubuloreticular structures in different types of myositis: implications for pathogenesis","volume":"32","author":"Bronner","year":"2008","journal-title":"Ultrastruct Pathol"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib61","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/life11070610","article-title":"New insights into profibrotic myofibroblast formation in systemic sclerosis: when the vascular wall becomes the enemy","volume":"11","author":"Romano","year":"2021","journal-title":"Life"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib63","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ajpath.2024.02.021","article-title":"TGF-beta1 drives integrin-dependent pericyte migration and microvascular destabilization in fibrotic disease","volume":"194","author":"Pellowe","year":"2024","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.berh.2026.102126_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110010","article-title":"Transcriptomic characterization of lung pericytes in systemic sclerosis-associated pulmonary fibrosis","volume":"27","author":"Renaud","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.berh.2026.102126_bib65","first-page":"1","article-title":"Pathogenic roles of autoantibodies in systemic sclerosis: current understandings in pathogenesis","author":"Sen\u00e9cal","year":"2019","journal-title":"J Scleroderma and Related Disorders"},{"issue":"11","key":"10.1016\/j.berh.2026.102126_bib66","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"suppl. 1","key":"10.1016\/j.berh.2026.102126_bib67","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.rhum.2025.10.420","article-title":"L\u2019activation de la voie mol\u00e9culaire de la fibrose est une caract\u00e9ristique de la scl\u00e9romyosite par rapport aux sous-groupes ACR\/EULAR de myosite","volume":"92","author":"Giannini","year":"2025","journal-title":"Rev Rhum"},{"issue":"12","key":"10.1016\/j.berh.2026.102126_bib68","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2026.102126_bib69","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2026.102126_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101668","article-title":"Cardiac involvement in systemic sclerosis: getting to the heart of the matter","volume":"35","author":"Bruni","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2026.102126_bib71","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1093\/rheumatology\/keab929","article-title":"Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey","volume":"61","author":"Hoa","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"suppl_5","key":"10.1016\/j.berh.2026.102126_bib73","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kex196","article-title":"Muscle involvement in systemic sclerosis: points to consider in clinical trials","volume":"56","author":"Walker","year":"2017","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib74","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/rheumatology\/keae407","article-title":"Muscle involvement in systemic sclerosis: high mortality not associated with nature of histological lesions","volume":"64","author":"Le Gouellec","year":"2025","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3899\/jrheum.171186","article-title":"Risk factors for future scleroderma renal crisis at systemic sclerosis diagnosis","volume":"46","author":"Gordon","year":"2019","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2026.102126_bib77","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.semarthrit.2013.09.008","article-title":"Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey","volume":"43","author":"Hudson","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40674-023-00206-y","article-title":"Systemic sclerosis associated myopathy: how to treat","volume":"9","author":"Selva-O'Callaghan","year":"2023","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.berh.2026.102126_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221092374","article-title":"Calcineurin inhibitors in systemic sclerosis - a systematic literature review","volume":"14","author":"Hofmann","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.berh.2026.102126_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40674-023-00214-y","article-title":"Intravenous immunoglobulins in idiopathic inflammatory myopathies: where are we?","volume":"10","author":"Gourbeyre-Masson","year":"2024","journal-title":"Curr Treat Option Rheum"},{"issue":"1","key":"10.1016\/j.berh.2026.102126_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102431","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients","volume":"19","author":"Chaigne","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102126_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152471","article-title":"Role of intravenous immunoglobulins in systemic sclerosis (SSc): a systematic literature review","volume":"68","author":"Koczanowski","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2026.102126_bib83","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","article-title":"Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study","volume":"72","author":"Elhai","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2026.102126_bib84","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40674-018-0113-3","article-title":"Exercise in myositis","volume":"4","author":"Alexanderson","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.berh.2026.102126_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.nut.2018.03.046","article-title":"Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis","volume":"55\u201356","author":"Siegert","year":"2018","journal-title":"Nutrition"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:46:36Z","timestamp":1781509596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1521694226000112"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102126","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scleromyositis \u2013 The new frontier","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102126"}}